{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:28Z","timestamp":1793298928563,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euf.2026.05.010","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T20:25:24Z","timestamp":1779481524000},"page":"859-861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early-access Use of Radioligand Therapy in Prostate Cancer"],"prefix":"10.1016","volume":"12","author":[{"given":"Chloe","family":"Fran\u00e7ois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-3287","authenticated-orcid":false,"given":"Clement","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.05.010_b0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.05.010_b0010","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","article-title":"177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: initial 254-patient results from a prospective registry (REALITY Study)","volume":"49","author":"Khreish","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euf.2026.05.010_b0015","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2967\/jnumed.125.270789","article-title":"PSMA PET\/CT-derived indicators and outcomes after [177Lu]Lu-PSMA-617: a multicenter retrospective analysis from the U.S. expanded-access program","volume":"67","author":"Kimura","year":"2026","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.05.010_b0020","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.2967\/jnumed.124.267816","article-title":"Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer: results from the U.S. expanded-access program and comparisons with Phase 3 VISION data","volume":"65","author":"Murthy","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.05.010_b0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1200\/JCO.2024.42.4_suppl.129","article-title":"Real-life data on [177Lu]Lu-PSMA-617: descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in France","volume":"42","author":"Roubaud","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.05.010_b0030","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.05.010_b0035","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2967\/jnumed.123.267321","article-title":"Safety and efficacy of extended therapy with [177Lu]Lu-PSMA: a German multicenter study","volume":"65","author":"Seifert","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.05.010_b0040","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.euf.2026.05.010_b0045","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00259-017-3681-9","article-title":"The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer","volume":"44","author":"Yordanova","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euf.2026.05.010_b0050","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000531246","article-title":"Efficacy and safety of actinium-225 prostate-specific membrane antigen radioligand therapy in metastatic prostate cancer: a systematic review and metanalysis","volume":"32","author":"Parida","year":"2023","journal-title":"Med Princ Pract"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:58:21Z","timestamp":1793296701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2405456926000787"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.05.010","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early-access Use of Radioligand Therapy in Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}